News
- Ezetimibe/simvastatin cuts cardiovascular events in CKD
- Published on Aug 08, 2011
Treatment with ezetimibe plus simvastatin (Inegy) significantly reduced major atherosclerotic events in patients with chronic kidney disease (CKD), whether or not they were on dialysis, the SHARP study has shown (Lancet 2011;377;2181–92).
- Funding for tailored cancer treatment
- Published on Aug 08, 2011
The Technology Strategy Board has announced Government funding totalling £6 million to support research into tumour profiling and data capture so that cancer treatments can be more accurately targeted to individual patients.
- Once-weekly exenatide approved
- Published on Aug 08, 2011
Bydureon, an extended-release formulation of exenatide 2mg, has received marketing approval in the EU, making it the first once-weekly GLP-1 agonist to reach the market.
- Nalmefene submission
- Published on Aug 08, 2011
Lundbeck says it will apply for EU marketing authorisation for nalmefene, its treatment for alcohol dependence, by the year end.
- Apixaban in AF
- Published on Aug 08, 2011
Apixaban (Eliquis), the oral direct Factor Xa inhibitor, is noninferior to warfarin in the prevention of stroke and systemic embolism in patients with atrial fibrillation plus at least one additional risk factor for stroke, say joint developers Bristol-Myers
